Baiyunshan (600332.SH): Selective RET small molecule inhibitor BYS10 enters key clinical trials.

Wisdom Finance and Economics APP news, Baiyunshan (600332.SH) announced that the company's subsidiary Baiyunshan Pharmaceutical Group Co., Ltd. Baiyunshan Pharmaceutical Factory (hereinafter referred to as "Baiyunshan Pharmaceutical Factory") received feedback from the National Medical Products Administration Drug Evaluation Center (hereinafter referred to as "CDE") on the selective RET small molecule inhibitor BYS10 tablet developed by Baiyunshan Pharmaceutical Factory.